Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …

Dispersion of tumors throughout the body is a neoplastic process responsible for the vast
majority of deaths from cancer. Despite disseminating to distant organs as malignant scouts …

Background The growth and recurrence of several cancers appear to be driven by a
population of cancer stem cells (CSCs). Glioblastoma, the most common primary brain …

The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has
been widely investigated, since it identifies cells that are able to initiate neurosphere growth …

The clinicopathological heterogeneity of glioblastoma (GBM) and the various genetic and
phenotypic subtypes in GBM stem cells (GSCs) are well described. However, the …

Background Glioblastomas are invasive therapy resistant brain tumors with extremely poor
prognosis. The Glioma initiating cell (GIC) population contributes to therapeutic resistance …

The identity of the cells that contribute to brain tumor structure and progression remains
unclear. Mesenchymal stem cells (MSCs) have recently been isolated from normal mouse …

Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …

Glioblastoma (GBM) is both the most common and the most lethal primary brain tumor. It is
thought that GBM stem cells (GSCs) are critically important in resistance to therapy …

Glioblastoma is the most common brain tumor. Median survival in unselected patients is< 10
months. The tumor harbors stem-like cells that self-renew and propagate upon serial …